Why G1 Therapeutics Stock Plunged 37.2% in September
Shares of G1 Therapeutics (NASDAQ: GTHX) fell 37.2% in September, according to data from S&P Global Market Intelligence, after investors reacted to trial data for some of the biopharmaceutical company's cancer drug candidates.
To be sure, shares plunged 33% on Monday, Sept. 30 alone following G1's weekend release of two separate updates. But that's not to say the data showed complete failure of those drug candidates.
Keeping in the mind the pullback came after a nearly 70% year-to-date pop for the stock, G1 first revealed the median overall survival for patients with metastatic triple-negative breast cancer who were treated with its trilaciclib drug candidate during a phase 2 trial was 20.1 months, compared with 12.6 months for patients who received only chemotherapy.
Source Fool.com
